A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
Sponsor: BeOne Medicines
This observational or N/A phase trial investigates Advanced Solid Tumor and is currently actively recruiting participants. BeOne Medicines leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)This study will be conducted in 2 phases: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
This study will be conducted in 2 phases: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Status Flow
Change History
5 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Contact Information
- BeOne Medicines
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auchenflower, Australia , Beijing, China , Birmingham, United States , Blacktown, Australia , Copenhagen, Denmark , Guangzhou, China , Harbin, China , Houston, United States , Houston, United States , Jinan, China and 6 more locations